Posterior Quadrant Disconnection for Childhood Onset Sub-Hemispheric Posterior Head Region Epilepsy: Indications in an Indian Cohort and Outcome.

BACKGROUND: Posterior quadrant disconnection (PQD) is an under-utilized surgical technique in the management of refractory epilepsy. There is a dearth of data pertinent to post-PQD seizure outcomes. METHODS: This retrospective study analyzed patients with drug-resistant childhood-onset epilepsy who underwent PQD at our center from 2009 to 2018. The clinical, imaging, and electrophysiological data were reviewed. The seizure outcome was noted from the latest follow-up in all patients. RESULTS: Fifteen patients underwent PQD, with a mean age at onset of epilepsy of 3.3 ± 4.6 years. All patients had seizure onset in childhood with focal onset of seizures, and in addition, 5 had multiple seizure types. All cases underwent presurgical workup with MRI, video-EEG, psychometry, while PET/MEG was done if required. Engel Ia and ILAE I outcomes were considered to be favorable. The histology of the specimen showed 9 patients (60%) had gliosis, 4 (26.7%) had focal cortical dysplasia (FCD), while 1 patient had nodular heterotopia and another had polymicrogyria-pachygyria complex. Postoperative follow-up was available in 14 cases. One patient was lost to follow-up. Mean follow-up duration for the cohort was 45 + 24 months. At last, follow-up (n = 14), 66.7% (10 cases) had favorable outcome (Engel Ia). At the end of 1-year follow-up, up to 73% (n = 11) of the patients were seizure-free. Four patients developed transient hemiparesis after surgery which improved completely by 3-6 months. CONCLUSIONS: Gliosis was more common etiology requiring PQD in our series than Western series, where FCD was more common. PQD is a safe and effective surgical modality in childhood-onset epilepsy with posterior head region epileptogenic focus.

Spinal Intramedullary Ganglioglioma in Children: An Unusual Location of a Common Pediatric Tumor.

Ganglioglioma is a common CNS tumor in children, mostly found in the temporal lobe, causing epilepsy. Spinal gangliogliomas are very rare, accounting for 1.1% of all intramedullary spinal tumors. The management principles and the need for adjuvant therapy are not yet well defined in this cohort. BRAF V600E mutation in spinal ganglioglioma has been described in a few series recently. In this report, we describe 3 children with spinal ganglioglioma at different locations, and their expression of BRAF V600E mutation and follow-up. In addition, we review the recent literature on pediatric spinal ganglioglioma management.

Determination of Collimator Helmet Factors for Leksell Gamma Knife 4C Unit Using GAF Chromic EBT3 Film and ImageJ Software.

BACKGROUND: Measurement of Collimator helmet factors (CHF) is an important quality assurance procedure to be performed on Leksell Gamma Knife unit at regular interval to make sure that the interchangeable collimator helmet fit into the source channels without any positional inaccuracy which leads to major treatment error. The primary aim of this study is to measure the CHFs for Elekta Leksell Gamma knife 4C helmets using GafChromic EBT3 film and Image J software. METHODS: GafChromic EBT3 film, EPSON expression 10000 XL scanner and Image J analysis software was used for this study. The calibration curve of GafChromic EBT3 film was generated with known dose values for 14 mm collimator helmet using ImageJ software. The collimator helmet factor (CHF) for 4mm, 8mm and 14 mm collimator helmets were measured by normalizing dose rates of 4mm, 8mm and 14 mm to the dose rate of 18 mm collimator helmet using the previously generated calibration curve. The measured CHF was compared to Elekta reference value and previously published mean values. RESULTS: The measured CHFs were 0.896, 0.958, and 0.986 for 4mm, 8mm and 14mm collimators respectively. The percentage difference obtained was 1.7 %, 0.21 %, 0.1 % between measured values and reference values. CONCLUSION: The measurement of CHFs in LGK 4C unit using GafChromic EBT3 film and ImageJ software is a reliable method to verify the manufacturer quoted CHFs in routine quality assurance procedures.